MA5-12823

antibody from Invitrogen Antibodies

Targeting: MAP2 MAP2A, MAP2B, MAP2C

Provider product page for MA5-12823

Western blot

Immunocytochemistry

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [31]
Comments [0]
Validations
Immunocytochemistry [1]
Immunohistochemistry [1]
Other assay [5]

Submit

Product number: MA5-12823 - Provider product page
Provider: Invitrogen Antibodies
Product name: MAP2 Monoclonal Antibody (AP20)
Antibody type: Monoclonal
Antigen: Other
Description: This antibody is specific to MAP2a and MAP2b, and will not cross-react with MAP1, MAP5, tubulin or tau. This clone reacts with dendrites and cell bodies of neurons but not with the neuronal processes. It does not react with the low MW form (70 kDa, MAP2c). The epitope has been mapped to aa 997-1332. The molecular weight of the doublet is ~280 kDa. For IHC staining, formalin-fixed tissues must be boiled in a 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at room temperature for 20 min. Recommened positive controls include human glioblastoma T98G cells or brain tissue.
Reactivity: Human, Bovine
Host: Mouse
Isotype: IgG
Antibody clone number: AP20
Vial size: 500 µL
Concentration: 0.2 mg/mL
Storage: 4° C

MAP2 protein structure - MA5-12823 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Differentiation of WTC-11 induced pluripotent stem cells (iPSC) into motor neurons (MN). a Schematic diagram of the overall experimental design. Shown are the small molecule stimuli for each developmental stage and the corresponding morphological changes in the course of iPSC conversion into MN. The scale bar for the phase contrast images is 400 mum; ( b ) Representative immunofluorescence images of key pluripotency (Oct4) and pan-neuronal (Nestin, Pax6, and beta-III tubulin) biomarkers indicated at efficient iPSC differentiation into neuronal stem cells (NSC) at day 7th post-induction (accumulation of Nestin is shown in orange). Upregulation of Pax6 and beta-III tubulin (shown in green) at day 13 of iPSC induction marked the formation of motor neuron progenitor (MNP) cells. c Immunostaining of neuronal structural proteins (beta-III-tubulin in green, MAP2 in orange), motor neuron specific markers (HB9 and ChAT in green), and synaptic vesicles protein (Synaptophysin in green) showed a pure population of mature MN at day 28 post-stimulation of iPSC. d Image quantification of Pax6- and HB9-labeled cells exemplified the percentage of cells that transitioned from NSC to MN. e Immunocytochemistry with anti-ISL1 antibody and quantitative analysis of biomarker positive cells at D28 of the differentiation protocol. The graphs show average of 6 cultures with > 300 cells in random fields for each culture. Scale bar: 100 mum

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 Neuronal survival is compromised in YAC128 1:3 CS co-cultures. DIV21 WT and YAC128 co-cultures were fixed at DIV21 and stained for MAP2 and DARPP32 (D32). ( a ) Sample fields of view at 20X objective (scale bar = 100 mum). The numbers of ( Bi ) MAP2+ and ( Bii ) DARPP32+ neurons per field of view are reduced in YAC128 1:3 co-cultures. ( Biii ) The proportion of DARPP32+ neurons (# DARPP32+ divided by # MAP2+) surviving at DIV21 is also significantly lower in YAC128 1:3 co-cultures [ n = 30 fields of view from three independent cultures; two-way ANOVA with Bonferroni post-hoc analysis; * p < 0.05, *** p < 0.001]

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 alphaSyn-induced caspase-3 activation and neuroinflammation. a Representative merged images showing immunostaining for microtubule-associated protein 2 (gray, MAP2), tyrosine hydroxylase (red, TH), and Cleaved Caspase-3 (green, CC3) in the brain channel at 6-days post-exposure to alphaSyn fibrils or alphaSyn monomers. Scale bars: 100 mum. b Quantitation of the number of CC3 and MAP2- or TH-positive neurons. Statistical analysis by two-way ANOVA with Tukey's multiple comparisons test (3-4 randomly selected different areas per chip, n = 3 independent chips/experimental group, ** P = 0.0033, **** P < 0.0001, NS not significant). Error bars represent mean +- SEM. Scale bars: 100 mum. c Immunostaining of the astrocyte marker glial fibrillary acidic protein (magenta, GFAP) demonstrated activation of astrocytes (white arrow) at day 6 post exposure to alphaSyn fibrils compared to monomeric alphaSyn. Scale bar, 100 mum. d Immunostaining of the microglial CD68 (red) demonstrated activation of microglia (white arrow) at day 6 post exposure to alphaSyn fibrils compared to monomeric alphaSyn. Scale bar, 100 mum. e The secreted levels of tumor necrosis factor-alpha (TNF-alpha) in the alphaSyn fibril model. Statistical analysis is two-sided unpaired t -test ( n = 6-7 independent chips, ** P = 0.0023). Error bars represent mean +- SEM. f The secreted levels of proinflammatory cytokine interleukin-6 (IL-6) in the alphaSyn fibril model. Statistical analysis is two-sided unpaired t -test

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. Identification of predictive markers of gemcitabine resistance. (a) Western blot analysis of possible predictive biomarkers shows evident overexpression of MAP2 and ANK3 in PANC1R cells compared with the sensitive PANC1, in concordance with the MS/MS results. NES was expressed too low to be quantified properly. (b) Evaluation of MAP2 expression in TMAs. Representative images of TMA cores (4x) and images at higher magnification (40x) of a positive and negative staining of MAP2 in the glandular tumour islands. As a negative control (4x), slides without primary antibody was used. As a positive control (10x), human brain cortex was used. MAP2, microtubule-associated protein 2; MS/MS, tandem mass spectrometry; NES, Nestin; PANC1, gemcitabine-sensitive cell line; PANC1R, gemcitabine-resistant PANC1 cell line; TMA, tissue microarray.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5. Immunofluorescence and immunohistochemistry of MAP2 in PANC1 and PANC1R cells and xenografts. (a) Immunofluorescence of PANC1 and PANC1R cells grown in chamber slides, and imaged at 100x magnification, showing a strong MAP2 (red)cytoplasmic staining in the PANC1R cells and low expression in PANC1, confirming our proteomic analysis. CK7 staining was performed as positive control (green), and DAPI was used to stain the nuclei (blue). This phenotype was conserved in our xenograft model as is shown by IHC (b), where MAP2 expression was overexpressed in the PANC1R tumours in vivo. DAPI, 4',6-diamidino-2-phenylindole; DFS, disease-free survival; IHC, immunohistochemistry; MAP2, microtubule-associated protein 2; OS, overall survival; PANC1, gemcitabine-sensitive cell line; PANC1R, gemcitabine-resistant PANC1 cell line.